|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | clinical course and prognostic factors of hepatorenal syndrome:a retrospective single-center cohort study显示文摘AIM: To investigate clinical and biochemical features of hepatorenal syndrome(HRS), to assess short and long- term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as a serum creatinine value > 1.5 mg/dL on at least two measurements within 48 h, admitted to our tertiary referral Unit from 2001 to 201, were retrospectively reviewed. Among them, 33 patients(53.2%) fulfilled the revised criteria of the International Ascites Club for the diagnosis of HRS. Twenty-eight patients were treated with combinations of terlipressin and albumin, two with dopamine and al- bumin, and three with albumin alone. No patients were suitable for liver transplantation. Complete response was defined as normalization of creatinine levels to less than 1.5 mg/dL, partial response as a decrease of at least 50% but not to less than 1.5 mg/dL, no response as no reduction in creatinine or a decrease of less 50% compared to pre-treatment values. All of the patients were followed up for at least 1 year until January 2013. RESULTS: HRS type 1 was diagnosed in 15 patients(45.5%). Hepatitis C virus infection was the primary etiology(69.6%), followed by alcohol(15.2%), and cryptogenesis(15.2%). Complete response to therapy was obtained in only 3 cases(9.1%) and partial re- sponse in 7 patients(21.2%). Median survival was 30 d(range: 10-274) without significant differences be- tween type 1 and type 2 HRS. By univariate analysis, Child-Pugh class C(P = 0.009), presence of hepatocel- lular carcinoma(P = 0.04), low serum sodium(P = 0.02), high bilirubin values(P = 0.009) and high Model for End-stage Liver Disease(MELD) score(P = 0.03) were predictive factors of 30-d mortality. By multivari- ate analysis, only serum sodium < 132 mEq/L(OR = 31.39; P = 0.02) and MELD score > 27(OR = 18.72; P = 0.01) were independently associated with a survival of less than one month. CONCLUSION: HRS still has a poor prognosis, even when vasoactive drug therapies are extensively used. | Anna Licata Marcello Maida Ambra Bonaccorso Fabio Salvatore Macaluso Maria Cappello Antonio Craxì Piero Luigi Almasio | 2013 | World Journal of Hepatology2013，5，12： | 2 |
| 2 | Predominant growth of Alcanivorax during experiments on “oil spill bioremediation” in mesocosms显示文摘 | Simone Cappello Renata Denaro Maria Genovese Laura Giuliano Michail M. Yakimov | 2006 | Microbiological Research2006，，2： | 1 |
| 3 | Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water-soluble polymers: in vitro/in vivo studies显示文摘 | Brunella Cappello Claudia Carmignani Maria Iervolino M Immacolata La Rotonda M Fabrizio Saettone | 2001 | International Journal of Pharmaceutics2001，，1： | 1 |
| 4 | Fecal Calprotectin in Clinical Practice: A Noninvasive Screening Tool for Patients With Chronic Diarrhea显示文摘 | Anna Licata Claudia Randazzo Maria Cappello Vincenza Calvaruso Giuseppe Butera Ada M. Florena Sergio Peralta Calogero Cammà Antonio Craxì | 2012 | Journal of Clinical Gastroenterology2012，，6： | 1 |
| 5 | Adalimumab in active ulcerative colitis: A “real-life” observational study显示文摘 | Alessandro Armuzzi Livia Biancone Marco Daperno Alessandra Coli Daniela Pugliese Vito Annese Annalisa Aratari Sandro Ardizzone Paola Balestrieri Fabrizio Bossa Maria Cappello Fabiana Castiglione Michele Cicala Silvio Danese Renata D’Incà Pietro Dulbecco G | 2013 | Digestive and Liver Disease2013，，： | 1 |
| 6 | Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance显示文摘 | Leonardo Marzio Lugina Cellini Maria Amitrano Rossella Grande Mariaelena Serio Giorgio Cappello Laurino Grossi | 2011 | European Journal of Gastroenterology & Hepatology2011，，6： | 1 |
| 7 | Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases:A multicenter study显示文摘AIM To assess the impact of short infliximab(IFX) infusion on hospital resource utilization and costs.METHODS All inflammatory bowel diseases(IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated.RESULTS One hundred and twenty-five patients were recruited(64 with ulcerative colitis and 61 with Crohn's disease). Median duration of disease was of 53 mo and mean age of pts at diagnosis was of 34 years(SD: ± 13). Adverse infusion reactions were reported in less than 4% both before and after short infusion. The total number of infusions across the selected centers was of 2501(30.5% short infusions). In the analyzed cohort, 1143 h were saved(762 in the infusion and 381 in observation phases) through the rapid IFX infusion protocol. This time saving(-15% compared to the standard protocol in infusion phase) represents, from the hospital perspective, an opportunity to optimize infusion unit capacity by allocating the saved time in alternative cost-effective treatments. This is the case of opportunity cost that represents the value of forgone benefit which could be obtained from a resource in its next-best alternative use. Hence, an extra hour of infusion in the case of standard 2-h IFX represents a loss in opportunity to provide other cost effective services. The analysis showed that the short infusion increased the infusion units capacity up to 50% on days when the IFX infusions were scheduled(infusion phase). Furthermore, the analysis showed that the short IFX infusion protocol leads to time savings also in the post-infusion phase(observation) leading to a time saving of 10% on average among the analyzed centers. Finally, the short infusion protocol has been demonstrated to lead to indirect cost savings of €138/patient(average-€17.300 on the whole cohort).CONCLUSION A short IFX infusion protocol can be considered time and cost saving in comparison to the standard infusion protocol both from the hospital's perspective, as it contributes to increase infusion units capacity, and the patients' perspective, as it reduces indirect costs and the impact of treatment on everyday life and work productivity. | Anna Viola Giuseppe Costantino Antonino Carlo Privitera Fabrizio Bossa Angelo Lauria Laurino Grossi Maria Beatrice Principi Nicola Della Valle Maria Cappello | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员